Detalimogene Voraplasmid Achieves 54% Complete Response in BCG-Unresponsive Bladder Cancer
A clinical study of detalimogene voraplasmid reported a 54% complete response rate in patients with heavily pretreated, BCG‑unresponsive non‑muscle‑invasive bladder cancer that also had carcinoma in situ.
The treatment‑related adverse events were generally low grade and reversible, indicating a manageable safety profile.
At the data cutoff, 96.8% of participants remained free from disease progression to stage T2 or higher, suggesting durable disease control.
These findings highlight the potential of detalimogene voraplasmid as a therapeutic option for a population with limited alternatives.
This writeup was produced by pharmadog from original reporting by onclive. The original article may no longer be reachable at its published URL.
Original headline: “Detalimogene Voraplasmid Yields 54% CR Rate in Heavily Pretreated BCG-Unresponsive NMIBC With CIS”
read at onclive ↗
comments(0)
5-min edit window · permanent after that